Quince Therapeutics regains Nasdaq listing compliance via equity alternative

Quince Therapeutics, Inc.

Company had been notified of MVLS deficiency on March 17, 2026.
On May 20, 2026, Staff confirmed compliance based on Q1 2026 stockholders' equity of $15.672M under Rule 5450(b)(1)(A).
Matter is now closed; no further action required.

item 8.01

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-234858

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.